Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential

被引:3
|
作者
Voutsadakis, Ioannis A. [1 ,2 ]
机构
[1] Sault Area Hosp, Algoma Dist Canc Program, 750 Great Northern Rd, Sault Ste Marie, ON P6B 0A8, Canada
[2] Northern Ontario Sch Med, Div Clin Sci, Sect Internal Med, Sudbury, ON P3E 2C6, Canada
来源
MEDICINA-LITHUANIA | 2022年 / 58卷 / 10期
关键词
colon cancer; cell line models; dependencies; targeted therapy; signal transduction; GENOMIC LANDSCAPE; EXPRESSION; SPECIFICITY; ENCORAFENIB; ACTIVATION; CETUXIMAB; PATHWAY; ARK5;
D O I
10.3390/medicina58101498
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Colorectal cancer represents a common malignancy and remains incurable in the metastatic stage. Identification of molecular alterations that are present in colorectal cancer has led to the introduction of targeted therapies that improve outcomes. BRAF and PIK3CA mutations are observed in a subset of colorectal cancers. Colorectal cancers bearing BRAF mutations may be treated with specific BRAF inhibitors. These drugs benefit patients with BRAF mutant colorectal cancers but responses are rather brief, and progression is the rule. In contrast, no PI3K inhibitors have proven successful yet in the disease. Thus, new treatments to supplement the currently available drugs would be welcome to further improve survival. Methods: Profiled colorectal cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) were examined for BRAF and PIK3CA mutations and were interrogated for molecular characteristics and concomitant alterations that mirror clinical sample alterations. The Genomics of Drug Sensitivity in Cancer (GDSC) project was used for determination of drug sensitivities of BRAF mutated colorectal cell lines with or without concomitant PIK3CA mutations. The Cancer Dependency Map project served as the basis for identification of molecular dependencies and vulnerabilities in these cell lines. Results: CCLE includes 84 colorectal cancer cell lines, which recapitulate the molecular landscape of colorectal cancer. Of these, 23 and 24 cell lines possess BRAF and PIK3CA mutations, respectively. Seven BRAF mutant cell lines have V600E mutations and 14 PIK3CA mutant cell lines have hotspot helical or kinase domain mutations. V600E BRAF mutant cell lines with or without hotspot PIK3CA mutations are heterogeneous in their MSI status and mimic colorectal cancer tissues in other prevalent abnormalities including APC and TP53 mutations. Essential genes for survival include CTNNB1, WRN, and pyrimidine metabolism enzyme CAD. Besides BRAF mutations, BRAF inhibitor sensitivity in colorectal cancer cell lines is conferred by SACS mutations and PRKN locus loss. Conclusions: Colorectal cancer cell lines bearing the frequent BRAF and PIK3CA mutations present many alterations of the parental cancer tissue. Described vulnerabilities represent leads for therapeutic exploration in colorectal cancers with the corresponding alterations.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] PIK3CA Mutated Colorectal Cancers Without KRAS, NRAS and BRAF Mutations Possess Common and Potentially Targetable Mutations in Epigenetic Modifiers and DNA Damage Response Genes
    Voutsadakis, Ioannis A.
    CANCER GENOMICS & PROTEOMICS, 2024, 21 (05) : 533 - 548
  • [22] A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
    Kawazoe, Akihito
    Shitara, Kohei
    Fukuoka, Shota
    Kuboki, Yasutoshi
    Bando, Hideaki
    Okamoto, Wataru
    Kojima, Takashi
    Fuse, Nozomu
    Yamanaka, Takeharu
    Doi, Toshihiko
    Ohtsu, Atsushi
    Yoshino, Takayuki
    BMC CANCER, 2015, 15
  • [23] Energy balance-related factors and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status
    Jenniskens, Josien C. A.
    Offermans, Kelly
    Simons, Colinda C. J. M.
    Samarska, Iryna
    Fazzi, Gregorio E.
    van der Meer, Jaleesa R. M.
    Smits, Kim M.
    Schouten, Leo J.
    Weijenberg, Matty P.
    Grabsch, Heike I.
    van den Brandt, Piet A.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (10) : 2723 - 2742
  • [24] Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer
    Soeda, Hiroshi
    Shimodaira, Hideki
    Watanabe, Mika
    Suzuki, Takao
    Gamoh, Makio
    Mori, Takahiro
    Komine, Keigo
    Iwama, Noriyuki
    Kato, Shunsuke
    Ishioka, Chikashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (04) : 670 - 677
  • [25] Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines
    Kostopoulou, Ourania N.
    Holzhauser, Stefan
    Lange, Birthe K. A.
    Ohmayer, Anna
    Andonova, Teodora
    Bersani, Cinzia
    Wickstrom, Malin
    Dalianis, Tina
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2019, 55 (06) : 1372 - 1384
  • [26] PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
    Sartore-Bianchi, Andrea
    Martini, Miriam
    Molinari, Francesca
    Veronese, Silvio
    Nichelatti, Michele
    Artale, Salvatore
    Di Nicolantonio, Federica
    Saletti, Piercarlo
    De Dosso, Sara
    Mazzucchelli, Luca
    Frattini, Milo
    Siena, Salvatore
    Bardelli, Alberto
    CANCER RESEARCH, 2009, 69 (05) : 1851 - 1857
  • [27] Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations
    Hasegawa, Kosei
    Kagabu, Masahiro
    Mizuno, Mika
    Oda, Katsutoshi
    Aoki, Daisuke
    Mabuchi, Seiji
    Kamiura, Shoji
    Yamaguchi, Satoshi
    Aoki, Yoichi
    Saito, Toshiaki
    Yunokawa, Mayu
    Takehara, Kazuhiro
    Okamoto, Aikou
    Ochiai, Kazunori
    Kimura, Tadashi
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 800 - 812
  • [28] Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases
    Zhang, Jing
    Zheng, Jianming
    Yang, Yinghong
    Lu, Junliang
    Gao, Jie
    Lu, Tao
    Sun, Jian
    Jiang, Hui
    Zhu, Yan
    Zheng, Yuhui
    Liang, Zhiyong
    Liu, Tonghua
    SCIENTIFIC REPORTS, 2015, 5
  • [29] High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases
    Brunsell, Tuva Host
    Sveen, Anita
    Bjornbeth, Bjorn Atle
    Rosok, Bard, I
    Danielsen, Stine Aske
    Brudvik, Kristoffer Watten
    Berg, Kaja C. G.
    Johannessen, Bjarne
    Cengija, Vanja
    Abildgaard, Andreas
    Guren, Marianne Gronlie
    Nesbakken, Arild
    Lothe, Ragnhild A.
    CLINICAL COLORECTAL CANCER, 2020, 19 (01) : E26 - E47
  • [30] KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania
    Brinzan, Costel Stelian
    Aschie, Mariana
    Cozaru, Georgeta Camelia
    Deacu, Mariana
    Dumitru, Eugen
    Burlacu, Ionut
    Mitroi, Anca
    MEDICINE, 2022, 101 (40) : E30979